TCS Helps Wiley Improve Customer Experience and Boost its Online Business
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, partnered with John Wiley & Sons, an American multinational publishing company, to modernize its ecommerce platform with SAP Commerce, creating a unified, seamless customer experience.
Built on a 200-year heritage of quality publishing, Wiley enables researchers, learners, universities, and corporations to develop skills and knowledge by delivering content in new and innovative ways to enrich the learning experience. The company’s legacy ecommerce platforms lacked scalability, flexibility and seamless customer experience, which constrained its ability to adopt new business models and make acquisitions.
Wiley partnered with TCS to modernize its ecommerce platform for the North America region, with a roadmap to extend it to the UK, Europe and Asia. TCS leveraged its deep contextual knowledge of Wiley’s business as well as its domain expertise to design and deploy the new platform using SAP Commerce. TCS also laid the foundation for headless commerce with flexible architecture that will enable faster time-tomarket and personalized customer experience across channels.
TCS designed a new user interface that simplified the shopping experience and enabled hassle-free checkouts without any lags. This and the improved resilience to traffic spikes, enhanced the customer experience and resulted in an 11% increase in the conversion rate and 40% reduction in bounce rate. Further, the new platform’s state-of-the-art features like real-time fraud checks and address verification provide increased security to Wiley
“With an objective to deliver exceptional experiences for our customers and employees, we needed to remodel our ecommerce business. Being in the publishing business, it is also an important revenue stream for us. With TCS, we were able to achieve a scalable commerce platform and create new and innovative ways to enrich our customers’ buying experience,” said David Levine, Sr. Director, eCommerce, Wiley. “We are positive that this strategic partnership with TCS will help us reach our long-term business goals and enhance omni-channel experience for our customers.”
“To remain competitive in today's rapidly changing digital landscape, companies are constantly looking for ways to provide their customers with the best online experiences with consistent and seamless interactions through innovative technologies,” said Akhilesh Tiwari, Global Head, Enterprise Application Services, TCS. “With this reimagined ecommerce platform, we believe that Wiley will take their commerce experience to the next level, drive business growth, and improve customer satisfaction and loyalty.”
Sun Pharma launches ‘Sunkalp’ on the occasion of National Doctors’ Day
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the launch of a special initiative ‘Sunkalp’ for the welfare of doctors, their families and the community.
Doctors have been working relentlessly through the pandemic putting their lives at risk to safeguard society. To recognise and care for their health & well-being, on the occasion of National Doctors' Day, Sun Pharma announces the launch of multifaceted initiatives under Sunkalp. These initiatives will be rolled out in a phased manner.
Mental health support for doctors & their families
Webinars for doctors on mental health by experts
Donation of Covid-19 medicines (phase 2)
Post Doctorate educational sponsorship (phase 2)
Educational aid for children of doctors who lost their lives to Covid-19 (phase 2)
Sun Pharma has committed Rs. 100 crores towards these initiatives, which includes donation of Covid19 medicines to communities at large through local & state government institutions.
For more than a year, doctors have been fighting the pandemic to save lives. Long stressful working hours, witnessing casualties and maintaining distance from loved ones have become normal for them. These factors can result in stress & exhaustion not only for them but also for their families. To help them cope with the same, Sun Pharma has partnered with Mann Talks to provide doctors and their families with confidential emotional and psychological care by trained mental health professionals. Further, to educate doctors on mental health issues & enable them to take better selfcare, multiple webinars will be held by experts.
Mastek enables multiple clients to deliver D2X Strategy
Mastek’s D2X strategy, which stands for Direct to Stakeholder, is designed to take People, Process, and Technology through Engagement to measurable growth for stakeholders.
Mastek through its experience in the Americas, and globally, enables organizations to interact, transact and serve any stakeholder e.g. Consumer, Employee, Agent, Broker, Distributor, B2B stakeholder online.
In a COVID and post COVID world, as engagement, transactions and service move online Mastek understands the importance of building highly performant platforms that deliver superior & differentiated experiences.
Mastek also delivers back office (e.g. ERP, SCM, CRM) transformation and strong integration with back office systems, thereby creating an agile organization that can meet the changing needs of stakeholders online.
Mastek has partnered with Oracle to leverage Oracle CX Commerce Cloud to enable D2X transformation for our joint clients. In the last 4 quarters, Mastek and Oracle have together won 6 new clients across Industry Verticals.
According to Chase Kim, EVP of IT of Gear Coop “We chose Oracle and Mastek as our Transformation Partners. The Oracle Customer Experience Commerce solution best met our business needs while Mastek, as a D2X enablement partner with their vast experience in retailing, eCommerce, and diverse technology capabilities, fit our Implementation Partner needs. We see Mastek as the partner that can help us unlock the potential of our Gear Coop owned Commerce channel.”
Raman Sapra, President Master Americas said “We are delighted to work with Gear Coop on their Digital journey. We have been a strategic partner of Oracle and will continue to leverage the Oracle platform to deliver value to our joint clients. At Mastek Americas, we are constantly creating business use cases for the industries we serve. This allows us to deliver significant business value to our clients through our D2X engagements’.
Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis
Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental New Drug Application (sNDA) to expand the use of SOLOSEC® (secnidazole) to include the treatment of trichomoniasis in adults. Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection (STI) in the U.S., affecting an estimated three to five million people every year.1 SOLOSEC® was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women. The supplemental approval makes SOLOSEC® the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.
“The FDA’s approval for the additional indication for SOLOSEC® to treat trichomoniasis builds upon our commitment to support women’s health and provides health care professionals with an option to treat patients with trichomoniasis and bacterial vaginosis (BV). Research demonstrates that approximately 70% of women with trichomoniasis are PCR positive for BV,2” said Jon Stelzmiller, President – Specialty, Lupin Pharmaceuticals, Inc. He also stated, “Additionally, having a treatment option for both trichomoniasis and BV that provides a complete course of therapy in a single dose will help address gaps in care related to adherence,3 and therefore, may reduce risk factors associated with trichomoniasis or BV,4,5 such as pelvic inflammatory disease (PID)6,7,8 and other STIs.9,10”
The approval is based, in part, on trial results that demonstrated a clinically and statistically significant cure rate of 92.2% for patients with trichomoniasis treated with SOLOSEC® (n=64) as compared to placebo (p<0.001) (n=67) in the modified intent-to-treat population, patients who had trichomoniasis and no other STIs (94.9% in the Per-Protocol population) in the landmark Phase 3 clinical trial. SOLOSEC® was generally well-tolerated. No serious adverse events were observed in the trial, and the most commonly reported adverse events were vulvovaginal candidiasis (2.7%) and nausea (2.7%). The data were recently published in Clinical Infectious Diseases in March 2021 and presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting.
SOLOSEC® is now available for both treatment of patients and their partners.11 The FDA approval of SOLOSEC® for the treatment of trichomoniasis in men was granted based on four open-label trials in males; one comparative study with metronidazole and ornidazole in males only and three single-arm studies in males and females.11 Parasitological evaluation was performed both pre- and posttreatment and reported cure rates ranging from 91.7% (165/180) to 100% (30/30) at time points ranging from two to 20 days (n=437, 211 males and 226 females)
“Trichomoniasis is a highly prevalent STI that can increase an individual’s risk for contracting or spreading other STIs, including human immunodeficiency virus (HIV). For approximately 70% of patients, trichomoniasis infection is asymptomatic.12,13,14 If left untreated, trichomoniasis can persist for months or years14 and result in adverse reproductive health outcomes, including infertility and preterm birth,3” said Steven Chavoustie, M.D., FACOG, CCRP, Obstetrician and Gynecologist, Segal Institute for Clinical Research. He also stated, “For these reasons, screening and treatment for trichomoniasis is crucial and I am pleased that there is a new treatment option available to help meet the needs of this patient population.”
Since trichomoniasis is a sexually transmitted disease, sexual partners should be treated with the same dose and at the same time, to prevent reinfection. Prescribers may consider presumptively treating partners by expedited partner therapy (EPT) where allowed by law.
HERO MOTOCORP SELLS MORE THAN A MILLION UNITS IN Q1 OF FY’22 DESPITE COVID-19 RELATED DISRUPTIONS
SELLS MORE THAN 4.6 LAKH MOTORCYCLES & SCOOTERS IN JUNE 2021
the world’s largest manufacturer of motorcycles and scooters, has commenced the Financial Year (FY) 2021-22 with sales of over a million units during the first quarter (April-June).
During this quarter, the auto industry witnessed significant disruptions triggered by the second wave of the Coronavirus pandemic, restricting movement of logistics and dampening customer sentiments.
Despite the unprecedented challenges, Hero MotoCorp sold 10,24,507 units of motorcycles and scooters in the first quarter of the fiscal – reflecting the strong resilience of the Indian economy and the inherent market demand for personal mobility.
With the gradual easing of the COVID-19 related restrictions and lockdowns across key markets in the country, the company witnessed a strong rebound in the month of June to sell 469,160 units of motorcycles and scooters.
In compliance with the guidelines as prescribed by state and local authorities, almost all of the customer touchpoints of Hero MotoCorp are now operational, with strict safety measures and protocols in place.
Heading into the upcoming festive season, the company remains cautiously optimistic about the customer demand in the coming months. The expected surge in personal mobility, forecast of a normal monsoon in several parts of the country and the improving rural sentiment are expected to lead to a swift revival in sales.
Hero MotoCorp highly appreciates the positive interventions by the government to revive the economy and provide support to industries impacted by the second-wave of COVID-19.
Till date, 92% of the entire workforce of Hero MotoCorp has been vaccinated with the first dose.